---
title: "Symbiotec Pharmalab Ltd (SYMBIOTEC) — Share Price, Financials & Analysis"
symbol: "SYMBIOTEC"
company: "Symbiotec Pharmalab Ltd"
canonical: "https://tapetide.com/stocks/SYMBIOTEC"
isin: "INE899I01028"
nse_symbol: "SYMBIOTEC"
bse_code: "544889"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
market_cap_cr: 7117.01
generated_at: "2026-09-13T19:17:21.270Z"
---

# Symbiotec Pharmalab Ltd (SYMBIOTEC)

Canonical page: https://tapetide.com/stocks/SYMBIOTEC

## Company

- **NSE Symbol:** SYMBIOTEC
- **BSE Code:** 544889
- **ISIN:** INE899I01028
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Listed Since:** 2026-09-01
- **Face Value:** ₹2
- **F&O Eligible:** No

## About

Symbiotec is a research-driven, science-
based pharmaceutical and biotechnology company with a strong global leadership position in Corticosteroid and Steroidal 
Hormone Active Pharmaceutical Ingredients (APIs). It has evolved from a Lab-Scale 
Steroid manufacturer into a fully integrated global platform.[1]

## Latest Price

- **Price:** ₹1133.45
- **Change:** -5.5 (-0.48%)
- **Open:** ₹1128
- **Day High:** ₹1148
- **Day Low:** ₹1105
- **Previous Close:** ₹1138.95
- **Volume:** 1010520
- **As Of:** 2026-09-11T10:28:50+00:00

## Key Fundamentals

Observed at 2026-09-11T04:33:25.591659Z.

- **Market Cap:** ₹7117.01 Cr
- **Classification:** Microcap
- **P/E (reported):** 66.6
- **Book Value:** ₹202.32
- **Price to Book:** 5.62
- **Dividend Yield:** 0%
- **ROE:** 9.56%
- **ROCE:** 14.26%
- **Debt to Equity:** 0.34
- **Revenue (yearly):** ₹872.3 Cr
- **Net Income:** ₹109.9 Cr
- **EBITDA:** ₹241 Cr
- **52-Week High:** ₹1193.7
- **52-Week Low:** ₹934.2

## Key Insights

### Strengths

- Company has reduced debt.

### Weaknesses

- Promoter holding is low: 33.3%
- Company has a low return on equity of 12.9% over last 3 years.
- Company might be capitalizing the interest cost

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 269.42% | -6.89% | 885.83% |
| ebitda margin growth | -63.56% | 1.28% | 12.04% | 41.98% |
| net income growth | -66.89% | 13.42% | 70% | -1% |
| revenue growth | -94.24% | 15.38% | 15% | 7% |
| roce | — | -3.26% | -3.58% | 13.42% |
| roe | — | -19.66% | 11.88% | -25.95% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Jun 2025 |
| --- | --- |
| Sales | 203 |
| Expenses | 145 |
| Operating Profit | 58 |
| OPM % | 29 |
| Other Income | 3 |
| Interest | 5 |
| Depreciation | 11 |
| Profit before tax | 45 |
| Tax % | 33 |
| Net Profit | 30 |
| EPS in Rs | 46.99 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 633 | 682 | 567 | 716 | 752 | 869 |
| Expenses | 438 | 550 | 497 | 544 | 549 | 630 |
| Operating Profit | 195 | 131 | 70 | 172 | 203 | 239 |
| OPM % | 31 | 19 | 12 | 24 | 27 | 27 |
| Other Income | 7 | 3 | 6 | 7 | 4 | -6 |
| Interest | 7 | 3 | 8 | 8 | 17 | 26 |
| Depreciation | 22 | 26 | 29 | 39 | 43 | 53 |
| Profit before tax | 173 | 105 | 39 | 132 | 147 | 153 |
| Tax % | 28 | 27 | 38 | 23 | 34 | 28 |
| Net Profit | 123 | 78 | 23 | 100 | 97 | 110 |
| EPS in Rs | 112.72 | 70.89 | 21.48 | 91.49 | 151.98 | 17.51 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 13 |
| Reserves | 510 | 588 | 611 | 704 | 804 | 1137 |
| Borrowings | 47 | 65 | 218 | 247 | 544 | 391 |
| Other Liabilities | 200 | 152 | 151 | 326 | 220 | 240 |
| Total Liabilities | 768 | 815 | 990 | 1289 | 1580 | 1781 |
| Fixed Assets | 261 | 280 | 299 | 448 | 438 | 1120 |
| CWIP | 28 | 40 | 182 | 208 | 568 | 64 |
| Investments | 5 | 5 | 5 | 4 | 1 | 4 |
| Other Assets | 474 | 490 | 504 | 628 | 572 | 592 |
| Total Assets | 768 | 815 | 990 | 1289 | 1580 | 1781 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 174 | 18 | 69 | 188 | 47 | 175 |
| Cash from Investing Activity | -96 | -32 | -220 | -206 | -307 | -227 |
| Cash from Financing Activity | -79 | 15 | 146 | 22 | 278 | 36 |
| Net Cash Flow | -1 | 1 | -5 | 3 | 19 | -16 |
| Free Cash Flow | 87 | -55 | -155 | -22 | -261 | -50 |
| CFO/OP | 112 | 36 | 124 | 129 | 40 | 99 |

### Ratios

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 68 | 77 | 72 | 64 | 85 | 83 |
| Inventory Days | 308 | 252 | 305 | 382 | 321 | 274 |
| Days Payable | 155 | 91 | 110 | 259 | 109 | 160 |
| Cash Conversion Cycle | 221 | 238 | 267 | 187 | 298 | 197 |
| Working Capital Days | 86 | 121 | 107 | 76 | -3 | -22 |
| ROCE % | — | 18 | 6 | 16 | 14 | 13 |

## Shareholding Pattern

### Quarterly

| Category | Dec 2025 |
| --- | --- |
| Promoters | 35.07% |
| FIIs | 0% |
| DIIs | 0% |
| Government | 0% |
| Public | 0% |
| Others | 64.93% |
| No. of Shareholders | 15 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Neutral
- **Buy / Neutral / Sell:** 0 / 19 / 0

### Moving Averages — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | — | Neutral |
| EMA (10) | — | Neutral |
| SMA (20) | — | Neutral |
| EMA (20) | — | Neutral |
| SMA (50) | — | Neutral |
| EMA (50) | — | Neutral |
| SMA (100) | — | Neutral |
| EMA (100) | — | Neutral |
| SMA (200) | — | Neutral |
| EMA (200) | — | Neutral |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | — | Neutral |
| MACD (12,26,9) | — | Neutral |
| Stochastic (14,3,3) | — | Neutral |
| ADX (14) | — | Neutral |
| Williams %R (14) | — | Neutral |
| ATR (14) | — | Neutral |
| ROC (12) | — | Neutral |
| Stoch RSI (14) | — | Neutral |
| UO (7,14,28) | — | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 11 Sep - Board meets on 21 Sep 2026 to approve Q1 FY27 standalone and consolidated results. | [Board Meeting Intimation for Prior Intimation Of The Meeting Of The Board Of Symbiotec Pharmalab Limited ('The Company') To Be Held On September 21, 2026 11 Sep - Board meets on 21 Sep 2026 to approve Q1 FY27 standalone and consolidated results.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a39e2d56-6226-4294-9d75-922538bc7fe5.pdf) |
| — | [Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 11 Sep](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9E30666F_D949_450E_9F56_9F5C157A486B_123017.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-03 | [Update On Intimation Under Regulation 8(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations 2015.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac0eaf21-1348-41cb-a5cd-78b4be63c741.pdf) |
| 2026-09-02 | [Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=092C47A3_3748_4A65_8648_35CCD139F911_170509.pdf) |
| 2026-09-01 | [Disclosure Under Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e5ee2538-58c7-43b2-9803-f64fdd7bd08d.pdf) |
| 2026-09-01 | [Intimation Under Regulation 8(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations 2015.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3c0e3c90-d992-4603-bebb-397513ddd4d7.pdf) |
| 2026-09-01 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ce2c28ae-db73-4851-8185-238e25f96a19.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:17:21.270Z.